Trial Profile
Prospective observational study on the efficacy and safety of EPA in advanced gastric cancer patients treated by S-1+CDDP as first line.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2017
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 02 Nov 2017 Status changed from recruiting to completed.
- 21 Jan 2015 New trial record